The CleoPen is set to break new ground in regenerative medicine, particularly in the areas of scar treatment, fine line and wrinkle reduction, and medical tattooing, among other applications.
The device represents the next step in the evolution of collagen induction therapy, a proven technique for encouraging the structural restoration of skin.
"We have added The CleoPen to our practice," explains Dr. David Krause of Kankakee, Illinois. "We see the results of collagen induction therapy, and our patients tell us it works. Our office is looking forward to introducing the new technology that The CleoPen has to offer."
The CleoPen distinguishes itself in terms of its versatility and optimization of well-researched, effective aesthetic procedures.
The device also allows practitioners to add platelet rich plasma (PRP) therapy to their aesthetic procedure toolset; PRP is a recently developed approach that uses the patient’s own blood to synthesize an effective and safe dermal filler.
"Our physician clients are skilled and caring problem solvers," says Rebecca Bell, CEO of RBELL Medical.
"We provide hands-on, expert assistance in their quest to provide a better quality of life to their patients. We do so by making an effort to bring additional tools to market and helping physicians navigate the regulatory and product launch process. RBELL Medical is a resource, not just a product."
Swiss-French dermatologist Dr. Phillipe Simonin pioneered the use of collagen induction therapy in 1994, when his study of 600 patients showed significant and dramatic results following just a few treatments.
Calling his therapy "Electroridopuncture," the process involved puncturing the skin repeatedly with small needles and thus stimulating the production of new melanin and collagen. Soon, dermatologists and cosmetic surgeons the world over were experimenting with and refining Dr. Simonin’s remarkable techniques.